GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Laboratorios Farmaceuticos Rovi SA (XMAD:ROVI) » Definitions » Cyclically Adjusted Revenue per Share

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Cyclically Adjusted Revenue per Share : €9.40 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's adjusted revenue per share for the three months ended in Dec. 2023 was €4.528. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.40 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Laboratorios Farmaceuticos Rovi's average Cyclically Adjusted Revenue Growth Rate was 16.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 18.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Laboratorios Farmaceuticos Rovi was 18.30% per year. The lowest was 9.80% per year. And the median was 15.10% per year.

As of today (2024-06-01), Laboratorios Farmaceuticos Rovi's current stock price is €87.75. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was €9.40. Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio of today is 9.34.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Laboratorios Farmaceuticos Rovi was 11.55. The lowest was 3.39. And the median was 5.65.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.30 5.68 6.73 8.08 9.40

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.43 8.73 9.08 9.40 -

Competitive Comparison of Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio falls into.



Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Laboratorios Farmaceuticos Rovi's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=4.528/121.2997*121.2997
=4.528

Current CPI (Dec. 2023) = 121.2997.

Laboratorios Farmaceuticos Rovi Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.154 100.139 1.398
201406 1.176 101.081 1.411
201409 1.142 100.441 1.379
201412 1.303 100.251 1.577
201503 1.223 99.474 1.491
201506 1.225 101.138 1.469
201509 1.142 99.559 1.391
201512 1.386 100.268 1.677
201603 1.230 98.638 1.513
201606 1.383 100.333 1.672
201609 1.270 99.737 1.545
201612 1.496 101.842 1.782
201703 1.369 100.896 1.646
201706 1.446 101.848 1.722
201709 1.311 101.524 1.566
201712 1.465 102.975 1.726
201803 1.536 102.122 1.824
201806 1.431 104.165 1.666
201809 1.472 103.818 1.720
201812 1.523 104.193 1.773
201903 1.483 103.488 1.738
201906 1.722 104.612 1.997
201909 1.684 103.905 1.966
201912 1.996 105.015 2.306
202003 1.823 103.469 2.137
202006 1.628 104.254 1.894
202009 2.004 103.521 2.348
202012 2.127 104.456 2.470
202103 2.357 104.857 2.727
202106 2.879 107.102 3.261
202109 3.132 107.669 3.529
202112 3.378 111.298 3.682
202203 3.813 115.153 4.017
202206 3.275 118.044 3.365
202209 3.801 117.221 3.933
202212 4.625 117.650 4.768
202303 3.850 118.948 3.926
202306 3.358 120.278 3.387
202309 4.038 121.343 4.037
202312 4.528 121.300 4.528

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Laboratorios Farmaceuticos Rovi  (XMAD:ROVI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Laboratorios Farmaceuticos Rovi's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=87.75/9.4
=9.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Laboratorios Farmaceuticos Rovi was 11.55. The lowest was 3.39. And the median was 5.65.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Laboratorios Farmaceuticos Rovi Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Laboratorios Farmaceuticos Rovi's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Business Description

Traded in Other Exchanges
Address
Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.

Laboratorios Farmaceuticos Rovi (XMAD:ROVI) Headlines

From GuruFocus

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 529,463 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 44,145 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 96,461 Shares

By GuruFocus Research GuruFocus Editor 03-04-2011

Rovi Corp. (ROVI) EVP & CFO James Budge sells 29,583 Shares

By GuruFocus Research GuruFocus Editor 01-07-2011

27% Upside potentially in Rovi Corporation

By Bavneet Singh Nagpal bavinagpal 03-17-2015

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 33,957 Shares

By GuruFocus Research GuruFocus Editor 01-05-2011

Rovi Corp. (ROVI) President and CEO Alfred J Amoroso sells 200,000 Shares

By GuruFocus Research GuruFocus Editor 03-19-2011

TiVo Corporation to Announce First Quarter 2020 Results

By Business Wire Business Wire 04-23-2020